A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2017
At a glance
- Drugs SGN CD70A (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 28 Oct 2016 Planned End Date changed from 1 Jun 2017 to 1 Mar 2017.
- 28 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Mar 2017.
- 27 Oct 2016 Status changed from recruiting to discontinued, according to Seattle Genetics media release.